

ForPatients

by Roche

Colorectal Cancer (CRC)

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Trial Status
Completed

Trial Runs In
23 Countries

Trial Identifier
NCT02291289 2014-001017-61
MO29112

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02291289 2014-001017-61 MO29112
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
